Lung Cancer
Conference Coverage
KRYSTAL-1: Clear activity of adagrasib in KRAS-mutated NSCLC
Phase 1/2 results with adagrasib confirm KRAS G12C as a druggable target in non–small cell lung cancer.
From the Journals
Melatonin not recommended for early-stage NSCLC
There was a hint of benefit with melatonin among patients with stage III/IV NSCLC.
News
Expert recommendations for targeted therapies in advanced NSCLC
The recommendations update guidance from 2017.
News
USPSTF expands criteria for lung cancer screening
The population now eligible for lung cancer screening has more than doubled.
News from the FDA/CDC
Pembrolizumab SCLC indication withdrawn in U.S.
The small cell lung cancer indication had been granted an accelerated approval, but a subsequent confirmatory study showed no survival benefit.
From the Journals
Study: Shared decision-making in lung cancer screening needs work
A cross-sectional study reports a host of shortcomings with shared decision-making between providers and patients in lung cancer screening.
From the Journals
Researchers identify four small cell lung cancer subtypes and their best therapies
News
FDA approves cemiplimab-rwlc for NSCLC with PD-L1 expression
This approval “means physicians and patients have a potent new treatment option against this deadly disease.”
Feature
Organ transplant patient dies after receiving COVID-19–infected lungs
A surgeon who handled the donor lungs was also infected with the virus and fell ill but later recovered.
News from the FDA/CDC
FDA approves first drug that protects against chemo-induced myelosuppression